Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
Product Information: Ozempic (semaglutide) injection, for subcutaneous use
Eli Lilly is developing tirzepatide for the treatment of type 2 diabetes mellitus (T2DM), obesity, cardiovascular disorders in T2DM, heart failure, non-alcoholic steatohepatitis, obstructive sleep apnoea and for reducing mortality/morbidity in obesity
These outcomes exceed what either medication typically achieves independently, especially in patients with insulin resistance as a primary driver of their metabolic dysfunction
The responsibility for Product safety, quality, labeling, and compliance lies entirely with the Seller." It is important to know that the company operates through several entities in the Netherlands and Cyprus
